Sodium challenge does not support an acute gastrointestinal-renal natriuretic signaling axis in humans

Kidney International

Volumn 82, Issue 12, 2012, Pages 1313-1320

  Preston, Richard A ^a,b,c   Afshartous, David ^d   Forte, Leonard R ^e   Rodco, Rolando ^a   Alonso, Alberto B ^a   Garg, Dyal ^a   Raij, Leopoldo ^a,f  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b JACKSON MEMORIAL HOSPITAL   (United States)

^c FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MISSOURI   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

GI renal signaling; proguanylin; prouroguanylin; sodium; sodium balance; sodium sensitivity

Indexed keywords

ALDOSTERONE; CREATININE; HORMONE PRECURSOR; PROGUANYLIN; PROUROGUANYLIN; SODIUM; UNCLASSIFIED DRUG;

ACUTE GASTROINTETINAL RENAL NATRIURETIC SIGNALING AXIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; CREATININE CLEARANCE; FOOD INTAKE; GLOMERULUS FILTRATION RATE; HORMONAL REGULATION; HORMONE BLOOD LEVEL; HUMAN; ORGAN SYSTEMS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SODIUM EXCRETION; SODIUM INTAKE;

EID: 84870619759     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.269     Document Type: Article

References (40)

1. Michell AR, Debnam ES, Unwin RJ. Regulation of renal function by the gastrointestinal tract: potential role of gut-derived peptides and hormones. Annu Rev Physiol 2008; 70: 379-403.
2. Thomas L, Kumar R. Control of renal solute excretion by enteric signals and mediators. J Am Soc Nephrol 2008; 19: 207-212.
3. Carey RM. Evidence for a splanchnic sodium input monitor regulating renal sodium excretion in man: lack of dependence upon aldosterone. Circ Res 1978; 43: 19-23.
4. Lennane RJ, Carey RM, Goodwin TJ et al. A comparison of natriuresis after oral and intravenous sodium loading in sodium-depleted man: evidence for a gastrointestinal or portal monitor of sodium intake. Clin Sci Mol Med 1975; 49: 437-440.
5. Moss NG, Fellner RC, Qian X et al. Uroguanylin, an intestinal natriuretic peptide, is delivered to the kidney as an unprocessed propeptide. Endocrinology 2008; 149: 4486-4498.
6. Qian X, Moss NG, Fellner RC et al. Circulating prouroguanylin is processed to its active natriuretic form exclusively within the renal tubules. Endocrinology 2008; 149: 4499-4509.
7. Forte LR. A novel role for uroguanylin in the regulation of sodium balance. J Clin Invest 2003; 112: 1138-1141.
8. Forte Jr LR. Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics. Pharmacol Ther 2004; 104: 137-162.
9. Forte LR, London RM, Freeman RH et al. Guanylin peptides: renal actions mediated by cyclic GMP. Am J Physiol Renal Physiol 2000; 278: F180-F191.
10. Hamra FK, Forte LR, Eber SL et al. Uroguanylin: structure and activity of a second endogenous peptide that stimulates intestinal guanylate cyclase. Proc Natl Acad Sci USA 1993; 90: 10464-10468.
11. Hess R, Kuhn M, Schulz-Knappe P et al. GCAP-II: isolation and characterization of the circulating form of human uroguanylin. FEBS Lett 1995; 374: 34-38.
12. Li Z, Perkins AG, Peters MF et al. Purification, cDNA sequence, and tissue distribution of rat uroguanylin. Regul Pept 1997; 68: 45-56.
13. Fan X, Hamra FK, Freeman RH et al. Uroguanylin: cloning of preprouroguanylin cDNA, mRNA expression in the intestine and heart and isolation of uroguanylin and urouroguanylin from plasma. Biochem Biophys Res Commun 1996; 219: 457-462.
14. Miyazato M, Nakazato M, Matsukura S et al. Uroguanylin gene expression in the alimentary tract and extra-gastrointestinal tissues. FEBS Lett 1996; 398: 170-174.
15. Perkins A, Goy MF, Li Z. Uroguanylin is expressed by enterochromaffin cells in the rat gastrointestinal tract. Gastroenterology 1997; 113: 1007-1014.
16. Nakazato M, Yamaguchi H, Date Y et al. Tissue distribution, cellular source, and structural analysis of rat immunoreactive uroguanylin. Endocrinology 1998; 139: 5247-5254.
17. Carrithers SL, Jackson BA, Cai WY et al. Site-specific effects of dietary salt intake on guanylin and uroguanylin mRNA expression in rat intestine. Regul Pept 2002; 107: 87-95.
18. Kinoshita H, Fujimoto S, Nakazato M et al. Urine and plasma levels of uroguanylin and its molecular forms in renal diseases. Kidney Int 1997; 52: 1028-1034.
19. Fukae H, Kinoshita H, Fujimoto S et al. Changes in urinary levels and renal expression of uroguanylin on low or high salt diets in rats. Nephron 2002; 92: 373-378.
20. Forte LR, Fan X, Hamra FK. Salt and water homeostasis: uroguanylin is a circulating peptide hormone with natriuretic activity. Am J Kidney Dis 1996; 28: 296-304.
21. Greenberg RN, Hill M, Crytzer J et al. Comparison of effects of uroguanylin, guanylin, and Escherichia coli heatstable enterotoxin STa in mouse intestine and kidney: evidence that uroguanylin is an intestinal natriuretic hormone. J Investig Med 1997; 45: 276-282.
22. Carrithers SL, Hill MJ, Johnson BR et al. Renal effects of uroguanylin and guanylin in vivo. Braz J Med Biol Res 1999; 32: 1337-1344.
23. Fonteles MC, Greenberg RN, Monteiro HS et al. Natriuretic and kaliuretic activities of guanylin and uroguanylin in the isolated perfused rat kidney. Am J Physiol 1998; 275(Pt 2): F191-F197.
24. Carrithers SL, Ott CE, Hill MJ et al. Guanylin and uroguanylin induce natriuresis in mice lacking guanylyl cyclase-C receptor. Kidney Int 2004; 65: 40-53.
25. Lorenz JN, Nieman M, Sabo J et al. Uroguanylin knockout mice have increased blood pressure and impaired natriuretic response to enteral NaCl load. J Clin Invest 2003; 112: 1244-1254.
26. Sindic A, Schlatter E. Cellular effects of guanylin and uroguanylin. J Am Soc Nephrol 2006; 17: 607-616.
27. Sindic A, Velic A, Basoglu C et al. Uroguanylin and guanylin regulate transport of mouse cortical collecting duct independent of guanylate cyclase C. Kidney Int 2005; 68: 1008-1017.
28. Sindic A, Hirsch JR, Velic A et al. Guanylin and uroguanylin regulate electrolyte transport in isolated human cortical collecting ducts. Kidney Int 2005; 67: 1420-1427.
29. Carrithers SL, Eber SL, Forte LR et al. Increased urinary excretion of uroguanylin in patients with congestive heart failure. Am J Physiol 2000; 278: H538-H547.
30. Sindic A, Schlatter E. Renal electrolyte effects of guanylin and uroguanylin. Curr Opin Nephrol Hypertens 2007; 16: 10-15.
31. Sindic A, Schlatter E. Mechanisms of action of uroguanylin and guanylin and their role in salt handling. Nephrol Dial Transplant 2006; 21: 3007-3012.
32. Singer DRJ, Markandu ND, Buckley MG et al. Contrasting endocrine responses to acute oral compared with intravenous sodium loading in normal humans. Am J Physiol (Renal Physiol) 1998; 274: F111-F119.
33. Gordon D, Peart WS. Sodium excretion in man, and adaptations to a lowsodium diet: effect of intravenous sodium intake. Clin Sci 1979; 57: 225-231.
34. Hurwitz S, Cohen RJ, Williams GH. Diurnal variation of aldosterone and plasma renin activity: timing relation to melatonin and cortisol and consistency after prolonged bed rest. J Appl Physiol 2004; 96: 1406-1414.
35. Scheving LA, Jin WH. Circadian regulation of uroguanylin and guanylin in the rat intestine. Am J Physiol 1999; 277(Pt 1): C1177-C1183.
36. Morrell C, Brant L. Using multivariate mixed-effects models to predict hypertension. Proc Joint Stat Meeting Biometrics Sec 2003: 2916-2921.
37. Fieuws S, Verbeke G. Joint modeling of multivariate longitudinal profiles: pitfalls of the random-effects approach. Stat Med 2004; 23: 3093-3104.
38. Heitjan D, Sharma D. Modelling repeated-series longitudinal data. Stat Med 1997; 16: 347-355.
39. R Project 2009. R - Version 2.9.1. Vienna: R Project (available from http://www.r-project.org).
40. Pinheiro J, Bates D. Mixed-Effects Models in S and S-Plus. Springer: New York, 2004.